Abstract
Injections of botulinum toxin have revolutionised the treatment of focal spasticity. Before their advent, the medical treatment for focal spasticity involved oral antispasticity drugs, which had decidedly non-focal adverse effects, and phenol injections. Phenol injections could be difficult to perform, could cause sensory complications and had effects that were of uncertain duration and magnitude. Furthermore, few neurologists knew how to perform them as they were mostly the province of rehabilitation specialists. Botulinum toxin can produce focal, controllable muscle weakness of predictable duration, without sensory adverse effects.
Randomised clinical trials (RCTs) involving patients with spasticity resulting f r om a variety of diseases (mainly stroke and multiple sclerosis) have clearly shown that botulinum toxin type A (Dysport® and Botox®) can temporarily (for approximately 3 months) reduce spastic hypertonia in the elbow, wrist and finger flexors of the upper limbs, and the hip adductors and ankle plantarflexors in the lower limbs. The clinical benefits from this reduction of neurological impairment are best shown in the upper limb, with less disability of passive function and reduced caregiver burden. In the lower limbs, there is improved perineal hygiene from hip adductor injections. The benefits of reducing ankle plantarflexor tone are less well established. Pain is also reduced, possibly by mechanisms other than muscle weakness. Improved active function has not yet been clearly demonstrated in RCTs, only in open-label trials. The safety of botulinum toxin-A is impressive, with minimal (mainly local) adverse effects.
There are little data on the use of botulinum toxin type B (Myobloc® or Neurobloc®) in spasticity and the only RCT that has examined this did not show tone reduction; dry mouth appeared to be a very common adverse effect. There are also very little data to allow a benefit-risk comparison of phenol and botulinum toxin injections; each have their clinical and technical advantages and disadvantages, and phenol is much less costly than botulinum toxin.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Naumann M, Toyka KV, Moore P. History and current applications of botulinum toxin: from poison to remedy. In: Naumann P, Moore P, editors. Handbook of botulinum toxin treatment. 2nd ed. Cambridge (MA), Blackwell Science, 2003: 3–8
Brin MF, Aoki KR. Botulinum toxin type A: pharmacology. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York(NY): WeMove Organization, 2002: 110–24
Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003 Jul-Aug; 43Suppl 1: S9–15
Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 2004 Mar; 19Suppl. 8: S162–7
Wong V. Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy. Pediatr Rehabil 2003 Apr-Jun; 6(2): 85–96
Sheean G. Use of botulinum toxin for spasticity. Expert Rev Neurother 2003; 3(6): 773–85
Sheean G. The treatment of musculoskeletal pain and spasm with botulinum toxin. Curr Pain Headache Rep 2002; 6: 460–9
Sheean G. Neurophysiology of Spasticity. In Barnes MP, Johnson G, editors. Clinical management of spasticity and the upper motor neurone syndrome. Cambridge: Cambridge University Press, 2001: 12–78
Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers, 1980: 485–94
Mayer NH, Simpson DM. Preface. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York(NY): We Move Organization, 2002
Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217–21
Landau WM. Spasticity: the fable of a neurological demon and the emperor’s new therapy. Arch Neurol 1974; 31: 217–9
Landau WM. Tizanidine and spasticity: neuromythology XIV. Neurology 1995; 45: 2295–6
Landau WM. Botulinum toxin for spasticity after stroke. N Engl J Med 2003 Jan 16; 348(3): 258–9
Dietz V. Spastic movement disorder: what is the impact of research on clinical practice? J Neurol Neurosurg Psychiatry 2003 Jun; 74(6): 820–1
Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28:512–5
Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306–10
Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265–9
Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2402–6
Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000; 69: 499–506
Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 8: 707–12
Smith SJ, Ellis E, White S, et al. A double-blind placebocontrolled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000; 14: 5–13
Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8(6): 559–65
Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 400
Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport®) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15(4): 289–300
Brashear A, McAfee AL, Kuhn ER, et al. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004 May; 85(5): 705–9
Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964 Apr; 192: 540–2
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987 Feb; 67(2): 206–7
Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001 Dec; 14(6): 771–6
Bakheit AM. Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry 2004 May; 75(5): 665–6
Satila H, Iisalo T, Pietikainen T, et al. Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites. Am J Phys Med Rehabil 2005; 84: 355–65
Steenbeek D, Meester-Delver A, Becher JG, et al. The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil 2005; 19: 274–82
Fehlings D, Rang M, Glazier J, et al. An evaluation of botulinum- A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 331–7
Koman LA, MooneyIII JF, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20: 108–15
Brashear A, McAfee AL, Kuhn ER, et al. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003 Jan; 84 (1): 103–7
Francis HP, Wade DT, Turner-Stokes L, et al. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 2004 Nov; 75 (11): 1547–51
Bhakta BB, Cozens JA, Bamford JM, et al. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996 Jul; 61(1): 30–5
Dengler R, Neyer U, Wohlfarth K, et al. Local botulinum toxin in the treatment of spastic drop foot. J Neurol 1992 Aug; 239(7): 375–8
Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995 Feb; 58(2): 232–5
Fock J, Galea MP, Stillman BC, et al. Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Inj 2004 Jan; 18(1): 57–63
Hesse S, Lucke D, Malezic M, et al. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994 Nov; 57(11): 1321–4
Hesse S, Krajnik J, Luecke D, et al. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996; 27: 455–60
Hesse S, Reiter F, Konrad M, et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo- controlled trial. Clin Rehabil 1998 Oct; 12(5): 381–8
Konstanzer A, Ceballos-Baumann AO, Dressnandt J, et al. Local injection treatment with botulinum toxin A in severe arm and leg spasticity. Nervenarzt 1993 Aug; 64(8): 517–23
Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000 Jul-Aug; 79(4): 377–84
Memin B, Pollak P, Hommel M, et al. Treatment of spasticity with botulinum toxin. Rev Neurol (Paris) 1992; 148(3): 212–4
Panizza M, Castagna M, di Summa A, et al. Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX). Funct Neurol 2000 Jul-Sep; 15(3): 147–55
Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996 Jul; 77(7): 717–21
Reiter F, Danni M, Lagalla G, et al. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998 May; 79(5): 532–5
Rodriquez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000 Jan-Feb; 79(1): 44–7
Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002 Jan; 249(1): 76–84
Sampaio C, Ferreira JJ, Pinto AA, et al. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997 Feb; 11(1): 3–7
Viriyavejakul A, Vachalathiti R, Poungvarin N. Botulinum treatment for post-stroke spasticity: low dose regime. J Med Assoc Thai 1998 Jun; 81(6): 413–22
Wang HC, Hsieh LF, Chi WC, et al. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002 Apr; 81(4): 272–8
Woldag H, Hummelsheim H. Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 2003; 50(3): 165–71
Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Neurol Sci 2005; 26: 32–9
Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 2002; 81: 770–5
Miscio G, Del Conte C, Pianca D, et al. Botulinum toxin in poststroke patients: stiffness modifications and clinical implications. J Neurol 2004; 251: 189–96
Finsterer J, Fuchs I, Mamoli B. Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol 1997 Jun; 20(3): 195–203
Oechsner M. Treatment of hip adductor spasticity with botulinum toxin type B. Nervenarzt 2002; 73: 1179–82
Sheean G. Neurophysiology of spasticity. In: Barnes MP, Johnson G, editors. Clinical management of spasticity and the upper motor neurone syndrome. Cambridge: Cambridge University Press, 2001: 12–78
Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001; 17: 2–10
Francis J, You S, Satorius A, et al. Analgesic properties and mechanism of action of botulinum toxin type A (Botox) [abstract]. 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Denver (CO); 2005 Jun
Verplancke D, Snape S, Salisbury CF, et al. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005; 19: 117–25
Reiter F, Danni M, Lagalla G, et al. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998; 79: 532–5
Hesse S, Jahnke MT, Luecke D, et al. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995; 201: 37–40
Page SJ, Elovic E, Levine P, et al. Modified constraint-induced therapy and botulinum toxin A: a promising combination. Am J Phys Med Rehabil 2003; 82: 76–80
Johnson CA, Wood DE, Swain ID, et al. A pilot study to investigate the combined use of botulinum neurotoxin type a and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke. Artif Organs 2002; 26: 263–6
Shaari CM, George E, Wu BL, et al. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991; 101(9): 960–4
Cote TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53(3): 407–15
Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999; 67(1): 90–3
Sheean GL, Murray NM, Marsden CD. Pain and remote weakness in limbs injected with botulinum toxin A for writer’s cramp. Lancet 1995; 346(8968): 154–6
Andrade LA, Borges V, Ferraz HB, et al. Botulinum toxin A: experience in the treatment of 115 patients. Arq Neuropsiquiatr 1997; 55: 553–7
Holzer SE, Ludlow CL The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope 1996; 106: 86–92
Tuite PJ, Lang AE. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996; 46: 846
Comella CL, Tanner CM, DeFoor-Hill L, et al. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiological findings. Neurology 1992; 42: 1307–10
Mezaki T, Kaji R, Kohara N, et al. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996; 46: 845–6
Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999 Oct 22; 53(7): 1439-4653 (7)
Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases [letter]. J Neurol Neurosurg Psychiatry 1997 Feb; 62(2): 198
Bakheit AM. Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol 2003; 10: 415–9
Borodic G. Myasthenic crisis after botulinum toxin [letter]. Lancet 1998; 352: 1832
Tarsy D, Bhattacharyya N, Borodic G. Myasthenia gravis after botulinum toxin A for Meige syndrome. Mov Disord 2000; 15: 736–8
Erbguth F, Claus D, Engelhardt A, et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 1235–6
Fasano A, Bentivoglio AR, Ialongo T, et al. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005; 64: 2155–6
Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991; 14: 672–5
Costa J, Espirito-Santo C, Borges A. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005; Jan 25(1): CD003633
Costa J, Espirito-Santo C, Borges A. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005; Jan 25(1): CD004315
Nebe A, Schelosky L, Wissel J, et al. No effects on heart-rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia. Mov Disord 1996; 11: 337–9
Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord 1995; 10: 574–9
Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992; 55: 844–5
Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34–8
Molgo J, Lemeignan M, Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987; 10: 464–70
Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981; 68: 50–4
Newman WJ, Davis TL, Padaliya BB, et al. Botulinum toxin type A therapy during pregnancy. Mov Disord 2004; 19: 1384–5
Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995 Sep; 45(9): 1743–6
Kessler KR, Skutta M, Benecke R, et al. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999; 246: 265–74
Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186–8
Comella CL, Jankovic J, Daggett S, et al. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type a treatment for cervical dystonia [abstract]. Presented at the 56 Annual Meeting of the AAN, San Francisco (CA), 2004. Neurology 2004; 62Suppl. 5: A511
Pistolesi D, Selli C, Rossi B, et al. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004; 171: 802–3
Khalili AA, Harmel MH, Forster S, et al. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964; 45: 513–9
Halpern D, Meelhuysen FE. Phenol motor point block in the management of muscular hypertonia. Arch Phys Med Rehabil 1966 Oct; 47(10): 659–64
Garland DE, Lilling M, Keenan MA. Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injured adults. Arch Phys Med Rehabil 1984 May; 65(5): 243–5
Nathan PW, Sears TA, Smith MC. Effects of phenol solutions on the nerve roots of the cat: an electrophysiological and histological study. J Neurol Sci 1965; 2(1): 7–29
Gracies J-M, Elovic E, McGuire JR, et al. Traditional pharmacologic treatments for spasticity. Part 1: local treatments. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move Organization, 2002: 44–65
Trigaux JP, Deceone B, Van Beers B. Focal necrosis of the ureter following CT-guided chemical sympathectomy Cardiovasc Intervent Radiol 1992; 15(3): 180–2
The Wemove Spasticity Study Group. Dosing, administration and a treatment algorithm for the use of botulinum toxin type A for adult-onset muscle overactivity in patients with an upper motorneuron lesion. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York (NY): WeMove Organization, 2002: 154–65
Kirazli Y, On AY, Kismali B, et al. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998 Nov-Dec; 77 (6): 510–15
Sheean G. Botulinum toxin treatment of spasticity: why is it so hard to show a functional benefit? Curr Opin Neurol 2002; 14: 771–6
Acknowledgements
No sources of funding were used to assist in the preparation of this review. Dr Sheean has served as a consultant to Allergan, Ipsen and Elan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sheean, G. Botulinum Toxin Treatment of Adult Spasticity. Drug-Safety 29, 31–48 (2006). https://doi.org/10.2165/00002018-200629010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200629010-00003